Kamada to Present at the Stifel 2024 Healthcare Conference
Kamada (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company specializing in rare and serious conditions and plasma-derived products, announced its participation in the Stifel 2024 Healthcare Conference in New York. CEO Amir London will deliver a corporate overview on November 18, 2024, at 10:55 a.m. ET. The event will be held from November 18-19, 2024. Investors can arrange one-on-one meetings through Stifel representatives, and a live webcast will be available on Kamada's website with a 30-day replay option.
Kamada (NASDAQ: KMDA; TASE: KMDA.TA), un'azienda biofarmaceutica globale specializzata in condizioni rare e gravi e prodotti derivati dal plasma, ha annunciato la sua partecipazione alla Stifel 2024 Healthcare Conference a New York. Il CEO Amir London presenterà una panoramica aziendale il 18 novembre 2024, alle 10:55 ora ET. L'evento si svolgerà dal 18 al 19 novembre 2024. Gli investitori possono organizzare incontri individuali tramite i rappresentanti di Stifel, e sarà disponibile una trasmissione in diretta sul sito web di Kamada con un'opzione di replay di 30 giorni.
Kamada (NASDAQ: KMDA; TASE: KMDA.TA), una empresa biofarmacéutica global especializada en condiciones raras y graves, así como en productos derivados del plasma, anunció su participación en la Stifel 2024 Healthcare Conference en Nueva York. El CEO Amir London ofrecerá una presentación corporativa el 18 de noviembre de 2024, a las 10:55 a.m. ET. El evento se llevará a cabo del 18 al 19 de noviembre de 2024. Los inversores pueden organizar reuniones uno a uno a través de representantes de Stifel, y habrá una transmisión en vivo disponible en el sitio web de Kamada con una opción de repetición de 30 días.
카마다 (NASDAQ: KMDA; TASE: KMDA.TA)는 희귀하고 심각한 질환 및 혈장 유래 제품 전문 글로벌 생명공학 회사로, 뉴욕에서 열리는 Stifel 2024 Healthcare Conference에 참가한다고 발표했습니다. CEO 아미르 론돈은 2024년 11월 18일 오전 10시 55분 ET에 기업 개요를 발표할 예정입니다. 이 행사는 2024년 11월 18일부터 19일까지 열립니다. 투자자들은 Stifel의 대표를 통해 일대일 미팅을 조정할 수 있으며, Kamada의 웹사이트에서는 30일 재생 옵션이 있는 실시간 웹캐스트를 이용할 수 있습니다.
Kamada (NASDAQ: KMDA; TASE: KMDA.TA), une entreprise biopharmaceutique mondiale spécialisée dans les maladies rares et graves ainsi que dans les produits dérivés du plasma, a annoncé sa participation à la Stifel 2024 Healthcare Conference à New York. Le PDG Amir London présentera un aperçu de l'entreprise le 18 novembre 2024 à 10h55 ET. L'événement se déroulera du 18 au 19 novembre 2024. Les investisseurs peuvent organiser des réunions individuelles via les représentants de Stifel, et un webinaire en direct sera disponible sur le site de Kamada avec une option de rediffusion de 30 jours.
Kamada (NASDAQ: KMDA; TASE: KMDA.TA), ein globales biopharmazeutisches Unternehmen, das sich auf seltene und schwere Erkrankungen sowie plazmaabgeleitete Produkte spezialisiert hat, gab seine Teilnahme an der Stifel 2024 Healthcare Conference in New York bekannt. CEO Amir London wird am 18. November 2024 um 10:55 Uhr ET einen Unternehmensüberblick geben. Die Veranstaltung findet vom 18. bis 19. November 2024 statt. Investoren können über Vertreter von Stifel Einzelgespräche vereinbaren, und auf der Website von Kamada wird ein Live-Stream mit einer 30-tägigen Wiederholungsoption zur Verfügung stehen.
- None.
- None.
REHOVOT, Israel and HOBOKEN, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that Amir London, Chief Executive Officer, will present a corporate overview at the Stifel 2024 Healthcare Conference, which will take place in New York, NY, on November 18 - 19, 2024.
Mr. London is scheduled to present at 10:55 a.m. Eastern Time on Monday, November 18, 2024. In addition to the presentation, Mr. London will be available for one-on-one investor meetings throughout the conference. Investors that are interested in arranging a meeting should contact their Stifel representative.
A live webcast and audio archive of the event may be accessed through the investor relations section of Kamada’s website at https://www.kamada.com/events-presentations/. The replay will be available for 30 days.
About Kamada
Kamada Ltd. (the “Company”) is a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, focused on diseases of limited treatment alternatives. The Company is also advancing an innovative development pipeline targeting areas of significant unmet medical need. The Company’s strategy is focused on driving profitable growth from its significant commercial catalysts as well as its manufacturing and development expertise in the plasma-derived and biopharmaceutical fields. The Company’s commercial products portfolio includes six FDA approved plasma-derived biopharmaceutical products: KEDRAB®, CYTOGAM®, WINRHO SDF®, VARIZIG®, HEPAGAM B® and GLASSIA®, as well as KAMRAB®, KAMRHO (D)® and two types of equine-based anti-snake venom (ASV) products. The Company distributes its commercial products portfolio directly, and through strategic partners or third-party distributors in more than 30 countries, including the U.S., Canada, Israel, Russia, Argentina, Brazil, India, Australia and other countries in Latin America, Europe, the Middle East, and Asia. The Company leverages its expertise and presence in the Israeli market to distribute, for use in Israel, more than 25 pharmaceutical products that are supplied by international manufacturers. During recent years the Company added eleven biosimilar products to its Israeli distribution portfolio, which, subject to the European Medicines Agency (EMA) and the Israeli Ministry of Health approvals, are expected to be launched in Israel through 2028. The Company owns an FDA licensed plasma collection center in Beaumont, Texas, which currently specializes in the collection of Anti-Rabies and Anti-D hyper-immune plasma used in the manufacturing of the Company’s relevant products and recently opened a new plasma collection center in Houston, Texas in which it collects normal source plasma and specialty plasma. In addition to the Company’s commercial operation, it invests in research and development of new product candidates. The Company’s leading investigational product is an inhaled AAT for the treatment of AAT deficiency, for which it is continuing to progress the InnovAATe clinical trial, a randomized, double-blind, placebo-controlled, pivotal Phase 3 trial. FIMI Opportunity Funds, the leading private equity firm in Israel, is the Company’s controlling shareholder, beneficially owning approximately
CONTACTS:
Chaime Orlev
Chief Financial Officer
IR@kamada.com
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578
britchie@LifeSciAdvisors.com
FAQ
When is Kamada (KMDA) presenting at the Stifel 2024 Healthcare Conference?
Where can I watch Kamada's (KMDA) Stifel Conference presentation?
How can investors meet with Kamada (KMDA) management at the Stifel Conference?